Scientific Considerations for Pharmacoenhancers in Antiretroviral Therapy-Reference-Cited by-同舟云学术

Scientific Considerations for Pharmacoenhancers in Antiretroviral Therapy

Published:2012-08 Issue:8 Volume:52 Page:1128-1133
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Arya Vikram,Robertson Sarah M.,Struble Kimberly A.,Murray Jeffrey S.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference20 articles.

1. Combination of protease inhibitors for the treatment of HIV-1 infected patients: a review of pharmacokinetics and clinical experience;Heeswijk;Antivir Ther,2001

2. A review of low-dose ritonavir in protease inhibitor combination therapy;Cooper;Clin Infect Dis,2003

3. Principles and practice of HIV-protease inhibitor pharmacoenhancement;Moyle;HIV Med,2001

4. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team;Hammer;N Engl J Med,1997

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on drug–drug interactions between antiretroviral therapies and drugs of abuse in HIV systems;Expert Opinion on Drug Metabolism & Toxicology;2020-08-31

2. The crosstalk between antiretrovirals pharmacology and HIV drug resistance;Expert Review of Clinical Pharmacology;2020-06-30

3. Antiretroviral Drug Metabolism in Humanized PXR-CAR-CYP3A-NOG Mice;Journal of Pharmacology and Experimental Therapeutics;2018-02-23

4. Atazanavir sulfate + cobicistat for the treatment of HIV infection;Expert Review of Anti-infective Therapy;2017-05-09

5. Investigational protease inhibitors as antiretroviral therapies;Expert Opinion on Investigational Drugs;2016-08-02